Defence Therapeutics Appoints Mark Lambermon as Head of Quality and Operations

“`html

10/02/2025 – 03:15 AM

Defence Therapeutics Bolsters Leadership with Key Quality & Operations Hire

Montreal, Quebec – Defence Therapeutics Inc. (OTCQB: DTCFF), a biotechnology firm specializing in drug delivery technologies, announced the appointment of Dr. Mark Lambermon as its Head of Quality and Operations. The move signals Defence’s commitment to scaling its operations as it advances its proprietary Accum® technology.

Dr. Lambermon boasts over two decades of experience in pharmaceutical R&D, biotech innovation, and commercial manufacturing. His resume includes key positions at industry giants AbbVie Inc. and Baxter Healthcare, where he spearheaded global CMC (Chemistry, Manufacturing, and Controls) programs, ensuring supplier and CDMO (Contract Development and Manufacturing Organization) oversight and implementing GMP (Good Manufacturing Practice)-compliant quality systems. Previous roles also include quality control oversight supporting FDA-regulated manufacturing and contributions to AAV-based gene therapies.

“Mark’s extensive expertise in quality, regulatory compliance and operations will be critical as we progress towards regulatory readiness,” stated Sébastien Plouffe, Founder and CEO of Defence Therapeutics. “His experience in designing quality systems, overseeing global supply chains, and preparing organizations for inspection readiness is precisely the leadership required to support our next growth stage and secure strong pharma partnerships.”

Dr. Lambermon’s appointment comes at a pivotal time for Defence Therapeutics, as the company is focused on advancing its Accum® platform. Accum® aims to enhance the targeted delivery of Antibody-Drug Conjugates (ADCs), potentially increasing their efficacy against cancer while reducing systemic toxicity. This proprietary platform represents a significant advancement in the field of oncology, and Dr. Lambermon’s role will be crucial in ensuring that the manufacturing and quality control processes meet the stringent requirements for regulatory approval.

“I’m thrilled to join Defence Therapeutics at this pivotal moment,” said Dr. Lambermon. “With Accum®, we have a real chance to improve outcomes and quality of life for patients facing aggressive cancers. My priority is to build a scalable, phase-appropriate Quality organization so that our scientific innovation is matched by operational excellence, regulatory compliance, and—above all—patient safety.”

As part of his compensation, Dr. Lambermon received 100,000 incentive stock options, exercisable at $0.80 per share with immediate vesting and a three-year exercise period. This equity stake aligns his interests with those of the shareholders, incentivizing him to contribute to the long-term success of the company.

Analysis: The appointment of Dr. Lambermon addresses a key need for Defence Therapeutics as it transitions from a research-focused organization to a clinical-stage company. His proven track record in establishing and maintaining GMP-compliant quality systems is essential for navigating the complex regulatory landscape of the pharmaceutical industry. The immediate vesting of stock options is a strategic move by Defence, ensuring Dr. Lambermon’s commitment from day one. While the stock options will result in dilution for existing shareholders, the enhanced expertise and operational excellence that Dr. Lambermon brings to the company are anticipated to generate greater value in the long run. Investors will be watching to see how Dr. Lambermon’s leadership contributes to the successful clinical trials and eventual commercialization of Defence Therapeutics’ innovative ADC products.

Dr. Lambermon holds a PhD in Cellular Biology from the University of Basel, Switzerland, and completed postdoctoral fellowships at the University of Toronto and Radboud University in The Netherlands.

About Defence:
Defence Therapeutics is a clinical-stage biotechnology company specializing in ADC products. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells.

Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions.

Neither the CSE nor its market regulator accepts responsibility for the adequacy or accuracy of this release.

Who is the new Head of Quality and Operations at Defence Therapeutics (DTCFF)?

Dr. Mark Lambermon has been appointed as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D, biotech innovation, and commercial manufacturing.

What is Dr. Lambermon’s background and experience before joining Defence Therapeutics?

Dr. Lambermon previously held roles at AbbVie Inc. and Baxter Healthcare, where he led global CMC programs and implemented GMP-compliant quality systems. He holds a PhD in Cellular Biology from the University of Basel.

What stock options were granted to Dr. Lambermon by Defence Therapeutics?

Dr. Lambermon was granted 100,000 stock options that vest immediately, exercisable at $0.80 per share for three years from the grant date.

How will Dr. Lambermon’s appointment benefit Defence Therapeutics’ development of Accum?

Dr. Lambermon will focus on building a scalable Quality organization to support Accum’s development through operational excellence, regulatory compliance, and patient safety measures.

“`